AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS

 

FOREMOST Study Finds Oral Otezla® (apremilast) Significantly Improved Disease Control vs. Placebo Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego. https://www.biospace.com/article/releases/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023/